Studies have shown that peanut oral immunotherapy (OIT) -- ingesting small, controlled amounts of peanut protein -- can desensitize adults and children and prevent allergic reactions, but the optimal duration and dose is unknown. In a study that followed participants after successful OIT, discontinuing OIT or continuing OIT at a reduced dose led to a decline in its protective effects. The study also found that blood tests administered before OIT could predict the success of therapy.
